Azimilide Reduces Emergency Department Visits and Hospitalizations in Patients With an Implantable Cardioverter-Defibrillator in a Placebo-Controlled Clinical Trial
Paul Dorian, MD, FACC*,*,
Hussein R. Al-Khalidi, PhD, FAHA ,
Stefan H. Hohnloser, MD, FACC ,
Jose M. Brum, MD, MSc ,
Preston M. Dunnmon, MD, FACC ,
Craig M. Pratt, MD, FACC ,
Michael J. Holroyde, PhD ,
Peter Kowey, MD, FACC|| on behalf of the SHIELD (SHock Inhibition Evaluation with AzimiLiDe) Investigators
* Division of Cardiology, St. Michael's Hospital/University of Toronto, Toronto, Ontario, Canada
Health Care Research Center, Procter & Gamble Pharmaceuticals, Cincinnati, Ohio
Department of Cardiology, Division of Electrophysiology, J.W. Goethe-University, Frankfurt, Germany
Methodist DeBakey Heart Center, Houston, Texas
|| Division of Cardiovascular Diseases, Jefferson Medical College, Philadelphia, Pennsylvania

View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Cumulative Risk of Recurrent Cardiac-Related ED Visits or Hospitalizations Over Time by Treatment Group
The slope of each curve represents the estimated rate of total cardiac-related ED visits or hospitalizations within each group. Abbreviations as in Figure 1.
|
|

View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Kaplan-Meier Cumulative Incidence of Cardiac Arrhythmic-Related ED Visits and Hospitalizations
ATP = antitachycardia pacing; ED = emergency department; ICD = implantable cardioverter-defibrillator.
|
|
|